COMPANY OVERVIEW
 

 

Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. We are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Our operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science.

We are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Our focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases.

Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals.

 

Transave's approach aims to significantly reduce risk and enhance success in drug development by avoiding the inherent uncertainties of new chemical entities ("NCEs"). By applying our proprietary liposomal delivery technology to well-established products that have already been approved by regulatory authorities, Transave has the potential to create new, improved profiles for these agents by enabling better delivery of the compound directly to the lung via inhalation. Compared to the original compounds, the Transave liposomal technology formulations may result in a product with the following benefits:

  1. Improved pharmacokinetic and pharmacodynamic profile;
  2. Prolonged drug exposure in the lung offering the potential for improved efficacy;
  3. Reduced systemic exposure of the drug in the blood and other vital organs, potentially resulting in an improved safety profile;
  4. Less frequent dosing, resulting in more convenience and the potential for improved patient compliance, and perhaps better patient outcomes;
  5. Ability to treat different diseases than is possible with the compound in its original formulation.

The actual benefits will need to be determined based on the results of well-controlled clinical trials.